Recombinate
Executive Summary
Baxter files PLA and ELA for the recombinant Factor VIII product for prevention and control of bleeding episodes in individuals with hemophilia A, Baxter said May 3. Recombinate was developed by Genetics Institute and is licensed to Baxter on an exclusive, worldwide basis. Last year, Genetics Institute and Genetech, which is developing a Factor VII for marketing by its licensee Miles through its Cutter Biological business, avoided a court patent battle by entering a cross-licensing arrangement for the product ("The Pink Sheet" March 27, 1989, p. 5). Baxter's Hyland Division will eventually market Recombinate.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.